What is Pharmaseal?
PHARMASEAL is a technology provider specializing in cloud-based Clinical Trial Management Systems (CTMS) and electronic Trial Master Files (eTMF). Their flagship product, Engility® CTMS eTMF, is engineered to streamline the complexities of clinical trial management across diverse sectors, including biopharma, medical devices, animal health, and contract research organizations. By offering a unified platform for both trial and document management, PHARMASEAL facilitates enhanced collaboration between sponsors and suppliers. The system's design emphasizes rapid implementation and seamless integration with Electronic Data Capture (EDC) systems, aiming to significantly reduce operational costs and accelerate trial timelines. PHARMASEAL's solutions are scalable, supporting organizations of all sizes in achieving greater oversight and control over their clinical trial processes.
How much funding has Pharmaseal raised?
Pharmaseal has raised a total of $704K across 1 funding round:
Other Financing Round
$704K
Other Financing Round (2019): $704K, investors not publicly disclosed
What's next for Pharmaseal?
The recent major strategic investment positions Pharmaseal for accelerated growth and market expansion. This capital infusion is expected to fuel further development of its Engility® CTMS eTMF platform, potentially enhancing features related to data analytics, regulatory compliance, and interoperability. The company's focus on streamlining clinical trial management suggests a strategic direction towards capturing a larger share of the growing clinical research technology market. Future initiatives may include expanding its client base within existing sectors and exploring new therapeutic areas or geographical markets. The company's ability to secure significant enterprise-level funding indicates strong investor confidence in its business model and its potential to disrupt traditional clinical trial management paradigms.
See full Pharmaseal company page
